PT  - JOURNAL ARTICLE
AU  - Sibel Z. Aydin
AU  - Joanna C. Robson
AU  - Antoine G. Sreih
AU  - Catherine Hill
AU  - Fatma Alibaz-Oner
AU  - Sarah Mackie
AU  - Susan Beard
AU  - Ahmet Gul
AU  - Gülen Hatemi
AU  - Tanaz A. Kermani
AU  - Alfred Mahr
AU  - Alexa Meara
AU  - Nataliya Milman
AU  - Beverley Shea
AU  - Gunnar Tómasson
AU  - Peter Tugwell
AU  - Haner Direskeneli
AU  - Peter A. Merkel
TI  - Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018
AID  - 10.3899/jrheum.181072
DP  - 2019 Sep 01
TA  - The Journal of Rheumatology
PG  - 1198--1201
VI  - 46
IP  - 9
4099  - http://www.jrheum.org/content/46/9/1198.short
4100  - http://www.jrheum.org/content/46/9/1198.full
SO  - J Rheumatol2019 Sep 01; 46
AB  - Objective. The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group seeks to develop validated outcome measures for use in trials for large-vessel vasculitis (LVV).Methods. An international Delphi exercise conducted among investigators identified items considered important to measure active disease. In parallel, qualitative research with patients was conducted, including interviews and focus groups.Results. Next steps prioritized by the group for LVV include (1) defining disease states (remission, flare, and patient-acceptable symptom state) and (2) selection of patient-reported outcome tools.Conclusion. The ultimate goal is to develop an OMERACT-endorsed core set of outcome measures for use in clinical trials of LVV.